# US 2023/0263791 A1 · Structural analogues of methylphenidate as parkinson's disease-modifying agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263791 A1
- Document ID: US20230263791A1
- Status: Published application
- Kind: A1
- Application number: 18/006,927
- Filed: 2021-08-04
- Published: 2023-08-24
- Earliest claimed: 2020-08-05
- Assignees: Universita Degli Studi di Brescia; Universita' Degli Studi Di Milano
- Applicants: Universita' Degli Studi Di Brescia; Universita' Degli Studi Di Milano
- Inventors: Arianna BELLUCCI; Francesca LONGHENA; Ermanno VALOTI; Valentina STRANIERO; Andrea CASIRAGHI
- Web page: https://patentgrep.com/patent/US20230263791A1

## CPC

- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61P 25/16: Anti-Parkinson drugs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention describes compounds of formula (A) for use as Parkinson's disease modifying-agents, said formula (A). Surprisingly it has been found that the compounds of the invention can significantly reduce alpha-synuclein aggregation and stimulate the functional interaction between alpha-synuclein and Synapsin III.

## Claims

### Claim 1

A disease-modifying method of treating Parkinson's disease comprising administering to a subject in need thereof an effective amount of a disease-modifying agent compound of formula (A), said formula (A)
wherein
R is H, Alk;
R1 is H, Alk, OAlk, Ar;
R2 is H, Alk, OAlk, Ar;
R1 and R2 joined together can form an (hetero)aromatic ring;
R3 is Me, Et, Pr and i-Pr;
n=0,1; m=0,1; r=0,1;
including pharmaceutical acceptable salt thereof,
including threo and erythro racemates and (R,R) or (S,S) stereoisomers thereof,
excluding methyl 2-phenyl-2-piperidin-2-ylacetate.

### Claim 2 (depends on 1)

The compound for use according to claim 1 wherein
Alk is Me or Et;
Ar is Ph, thiophene or furane;

### Claim 3 (depends on 1)

The method according to claim 1 wherein
R is H, Me;
R1 is H, Me, OMe, Ph;
R2 is H, Me;
R1 and R2 joined together can form a phenyl ring.

### Claim 4 (depends on 1)

The method according to claim 1 wherein
R1 is other than H; and
R2 is H.

### Claim 5 (depends on 1)

The method according to claim 1 wherein
R═H;
R1=Me;
R2═H;
R3=Me;
n=0, m=0 and r=0.

### Claim 6 (depends on 1)

The method according to claim 1 wherein
R=Me;
R1=Me;
R2═H;
R3=Me;
n=0, m=0 and r=0.

### Claim 7 (depends on 1)

The method according to claim 1 wherein
R═H;
R1═H;
R2═H;
R3=Me;
n=1, m=0 and r=0.

### Claim 8 (depends on 1)

The method according to claim 1 having a threo configuration; and preferably being the (R,R) stereoisomer.

### Claim 9 (depends on 1)

The method according to claim 1 selected in the group consisting of

### Claim 10 (depends on 1)

A disease-modifying method of treating Parkinson's disease comprising administering to a subject in need thereof an pharmaceutical composition comprising an effective amount of a disease-modifying agent compound of formula (A) as defined in claim 1 and at least another pharmaceutically acceptable ingredient.
